Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > ORGANIZATION
ORGANIZATION
- Japan Citizen’s Group Opposes NIP Inclusion of Silgard 9
December 19, 2022
- Ease API Regulations to US and European Levels to Stop Generic Woes: JEMA
December 15, 2022
- Lilly’s Simone Thomsen to Become PhRMA Japan Chair in January
December 7, 2022
- FPMAJ Poll Finds Worsening Supply Woes with 28% of Drugs Restricted or Suspended
December 7, 2022
- 88% of Japanese Have Confidence in Pharma Industry: JPMA
December 6, 2022
- Exclude Patented Drugs from Off-Year Price Revision: JPMA, PhRMA, EFPIA
November 24, 2022
- Citizen’s Group Renews Opposition to Emergency Approval of Shionogi COVID-19 Pill
November 22, 2022
- Increasing Number of Lawmakers Are Against Off-Year Price Revision: JPMA Director General
November 18, 2022
- JPMA Lauds Govt’s Proposed Extra Budget for Enhanced Startup Support
November 10, 2022
- As Arrival of Alzheimer’s Meds Nears, Experts Talk over Financial Impact and ROI: Lilly/PhRMA Forum
November 9, 2022
- Priority of Japan Investment Lowered at 27% of Multinational Firms: JPMA Poll
November 2, 2022
- JPMA Applauds Drug Discovery Startup Support in New Economic Package
October 31, 2022
- Japan Needs New Forum for Top-Level Dialogue Including Global CEOs: PhRMA Chair
October 28, 2022
- Over 80% of Wholesaler Reps Say Shipment Adjustments Take Up Most of Their Time: Survey
October 21, 2022
- Look at Drug Prices as Long-Term Investment, Not as Cost: EFPIA President
October 7, 2022
- EFPIA Chief Prods Japan on Mutual Trial Data Recognition, Cooperation to Boost Attractiveness to Rival US, China
October 7, 2022
- EFPIA Japan Appoints Takafumi Horii as New Vice Chair
October 6, 2022
- JMA Chuikyo Rep Urges Savings from Off-Year Drug Price Cuts to Be Allocated to Medical Fees
October 5, 2022
- Generic Use Rate at 79.8% in April-June, Flat YOY: JGA
September 29, 2022
- Policy Veterans’ Group Proposes Simple Drug Price Maintenance Scheme for Patented Meds
September 28, 2022
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…